(Total Views: 287)
Posted On: 12/03/2020 7:39:25 PM
Post# of 36568
“This last time, it was about revenue for the S-1. That should be done and there should not be any reason that information has not been put in, since the deals have been done.
So, no reason for the S-1 not being approved now.”
Please don’t take offense. But all of the above has nothing to do with how S1s work. It’s hard to even follow. Generex endured a one year review of the 2019 K that Joe described as a deep dive. That held up Generex from having the S1s declared in Effect for nearly a year. That was detailed in the last update that it appears you never heard. Ngio on that end has 3 S1s. Two are all ready and all set. One that Joe will fill with his financing deal information that he was informed by the SEC will only be a limited review. That’s a positive. After a year delay due to SEC review, causing no funds to subsidiaries other than vaccines, it’s getting close to go time.
So, no reason for the S-1 not being approved now.”
Please don’t take offense. But all of the above has nothing to do with how S1s work. It’s hard to even follow. Generex endured a one year review of the 2019 K that Joe described as a deep dive. That held up Generex from having the S1s declared in Effect for nearly a year. That was detailed in the last update that it appears you never heard. Ngio on that end has 3 S1s. Two are all ready and all set. One that Joe will fill with his financing deal information that he was informed by the SEC will only be a limited review. That’s a positive. After a year delay due to SEC review, causing no funds to subsidiaries other than vaccines, it’s getting close to go time.
(2)
(0)
